Addition of exenatide BID to insulin glargine: A post-hoc analysis of the effect on glycemia and weight across a range of insulin titration

Current Medical Research and Opinion

Volumn 30, Issue 7, 2014, Pages 1209-1218

  Buse, John B ^a   Han, Jenny ^b   Miller, Stephan ^b   Macconell, Leigh ^b   Pencek, Richard ^b   Wintle, Matthew ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

Diabetes; Exenatide; GLP 1 receptor agonist; Insulin

Indexed keywords

EXENDIN 4; HEMOGLOBIN A1C; INSULIN GLARGINE; METFORMIN; PIOGLITAZONE; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; GLARGINE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; LONG ACTING INSULIN; PEPTIDE; VENOM;

ADD ON THERAPY; ADULT; AGED; ARTICLE; BACKACHE; BODY WEIGHT; CONSTIPATION; CONTROLLED STUDY; COUGHING; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSPEPSIA; FEMALE; GLYCEMIC CONTROL; HUMAN; HYPERTENSION; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 3 CLINICAL TRIAL; POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION; ADOLESCENT; BLOOD; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG COMBINATION; METABOLISM; MIDDLE AGED; TITRIMETRY; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN, LONG-ACTING; MALE; MIDDLE AGED; PEPTIDES; TITRIMETRY; TREATMENT OUTCOME; VENOMS; WEIGHT LOSS; YOUNG ADULT;

EID: 84903642756     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2014.896329     Document Type: Article

References (38)

1. Centers for Disease Control and Prevention. National diabetes fact sheet: National estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2011
2. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: A patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364-79
3. Garber AJ, Abrahamson MJ, Barzilay JI, et al. AACE comprehensive diabetes management algorithm 2013. Endocr Pract 2013;19:327-36
4. Seaquist ER, Anderson J, Childs B, et al. Hypoglycemia and diabetes: A report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care 2013;36:1384-95
5. Ross SA, Tildesley HD, Ashkenas J. Barriers to effective insulin treatment: Uhe persistence of poor glycemic control in type 2 diabetes. Curr Med Res Opin 2011;27(Suppl 3):13-20
6. Karl DM, Gill J, Zhou R, et al. Clinical predictors of risk of hypoglycaemia during addition and titration of insulin glargine for type 2 diabetes mellitus. Diabetes Obes Metab 2013;15:622-8
7. Bretzel R, Nuber U, Landgraf W, et al. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in patients with type 2 diabetes on oral hypoglycaemic agents (APOLLO): An open randomised controlled trial. Lancet 2008;371:1073-84
8. Pontiroli AE, Miele L, Marabito A. Increase of body weight during the first year of intensive insulin treatment in type 2 diabetes: Systematic review and metaanalysis. Diabetes Obes Metab 2011;13:1008-19
9. Russell-Jones D, Khan R. Insulin-Associated weight gain in diabetes-causes, effects and coping strategies. Diabetes Obes Metab 2007;9: 799-812
10. Anderson JW, Konz EC. Obesity and disease management: Effects of weight loss on comorbid conditions. Obesity Res 2001;9(Suppl 4):326-34
11. American Diabetes Association. Standards of medical care in diabetes-2013. Diabetes Care 2013;36(Suppl 1):S11-66
12. Göke R, Fehmann HC, Linn T, et al. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-Amide an antagonist at the glucagon-like peptide 1-(7-36)-Amide receptor of insulin-secreting b-cells. J Biol Chem 1993;268: 19650-5
13. DeFronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-Treated patients with type 2 diabetes. Diabetes Care 2005;28:1092-100
14. Drucker DJ, Nauck MA. The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-705
15. Diamant M, Van Gaal L, Stranks S, et al. Safety and efficacy of once-weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes over 84 weeks. Diabetes Care 2012;35:683-9
16. Kolterman OG, Buse JB, Fineman MS, et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2003;88:3082-9
17. Buse JB, Bergenstal RM, Glass LC, et al. Use of twice-daily exenatide in basal insulin-Treated patients with type 2 diabetes: A randomized, controlled trial. Ann Intern Med 2011;154:103-12
18. Perfetti R. Combining basal insulin analogs with glucagon-like peptide-1 mimetics. Diabetes Tech Ther 2011;13:873-81
19. Rosenstock J, Fonseca V. Missing the point: Substituting exenatide for nonoptimized insulin: Going from bad to worse! Diabetes Care 2007;30:2972-3
20. Rosenstock J, Shenouda SK, Bergenstal RM, et al. Baseline factors associated with glycemic control and weight loss when exenatide twice daily is added to optimized insulin glargine in patients with type 2 diabetes. Diabetes Care 2012;35:955-8
21. Rodbard HW, Blonde L, Braithwaite SS, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 2007;13(Suppl 1): 1-68
22. Hirsch IB, Bergenstal RM, Parkin CG, et al. A real-world approach to insulin therapy in primary care practice. Clin Diabetes 2005;23:78-86
23. Kruger DF. Intensifying insulin treatment: Options, practical issues, and the role of the nurse practitioner. J Am Acad Nurse Pract 2012;24:260-9
24. Riddle MC, Rosenstock J, Gerich J. The Treat-To-Target trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26:3080-6
25. Davies MJ, Donnelly R, Barnett AH, et al. Exenatide compared with long-Acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: Results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study. Diabetes Obes Metab 2009;11:1153-62
26. Gentilella R, Bianchi C, Rossi A, et al. Exenatide: A review from pharmacology to clinical practice. Diabetes Obes Metab 2009;11:544-56
27. de Pablos-Velasco P, Parhofer KG, Bradley C, et al. Current level of glycaemic control and its associated factors in patients with type 2 diabetes across Europe: Data from the PANORAMA study. Clin Endocrinol (Oxf) 2014;80:47-56
28. Ahren B. Avoiding hypoglycemia: A key to success for glucoselowering therapy in type 2 diabetes. Vasc Health Risk Manag 2013;9:155-63
29. Moghissi E, Ismail-Beigi F, Devine RC. Hypoglycemia: Minimizing its impact in type 2 diabetes. Endocr Pract 2013;19:526-35
30. Cryer PE, Davis SN, Shamoon H. Hypoglycemia in diabetes. Diabetes Care 2003;26:1902-12
31. Yaubovich N, Gerstein HC. Serious cardiovascular outcomes in diabetes: Uhe role of hypoglycemia. Circulation 2011;123:342-8
32. Anderson JW, Kendall CWC, Jenkins DJA. Importance of weight management in type 2 diabetes: Review with meta-Analysis of clinical studies. J Am Coll Nutr 2003;2:331-9
33. Feldstein AC, Nichols GA, Smith DH, et al. Weight change in diabetes and glycemic and blood pressure control. Diabetes Care 2008;31:1960-5
34. Look AHEAD Research Group. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes. Diabetes Care 2007;30:1374-83
35. Stevens J, Erber E, Truesdale KP, et al. Long-And short-Term weight change and incident coronary heart disease and ischemic stroke. Am J Epidemiol 2013;178:239-48
36. Blonde L, Klein EJ, Han J, et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 2006;8:436-47
37. Holman RR, Thorne KI, Farmer AJ, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007;357:1716-30
38. Davies M, Storms F, Shutler S, et al. Improvement of glycemic control in subjects with poorly controlled type 2 diabetes. Diabetes Care 2005;28:1282-8.